Nurix Therapeutics, Inc.
NRIX
$15.60
-$0.13-0.83%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.95% | 48.32% | 41.86% | -30.25% | -29.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.95% | 48.32% | 41.86% | -30.25% | -29.15% |
| Cost of Revenue | 42.99% | 47.51% | 37.64% | 24.80% | 17.17% |
| Gross Profit | -39.41% | -47.20% | -35.69% | -64.40% | -48.97% |
| SG&A Expenses | 14.80% | 8.27% | 7.70% | 2.05% | 7.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.15% | 40.29% | 32.07% | 20.52% | 15.31% |
| Operating Income | -34.10% | -37.96% | -28.67% | -46.62% | -37.38% |
| Income Before Tax | -36.42% | -38.09% | -25.27% | -43.96% | -34.28% |
| Income Tax Expenses | 181.48% | 193.13% | 372.22% | 100.00% | -- |
| Earnings from Continuing Operations | -36.62% | -38.32% | -25.65% | -43.99% | -34.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.62% | -38.32% | -25.65% | -43.99% | -34.47% |
| EBIT | -34.10% | -37.96% | -28.67% | -46.62% | -37.38% |
| EBITDA | -35.37% | -39.14% | -29.01% | -47.34% | -37.65% |
| EPS Basic | -5.27% | -1.92% | 10.47% | -5.92% | -9.10% |
| Normalized Basic EPS | -5.12% | -1.75% | 10.74% | -5.88% | -8.93% |
| EPS Diluted | -5.27% | -1.92% | 10.47% | -5.92% | -9.10% |
| Normalized Diluted EPS | -5.12% | -1.75% | 10.74% | -5.88% | -8.93% |
| Average Basic Shares Outstanding | 29.14% | 34.85% | 40.78% | 36.16% | 23.52% |
| Average Diluted Shares Outstanding | 29.14% | 34.85% | 40.78% | 36.16% | 23.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |